# SHR-A2102 (NCT05701709)

> Phase I Study of SHR-A2102 in Patients With Advanced Solid Tumors

No report yet. It can be ordered.

## Registry

- Registry record: https://clinicaltrials.gov/study/NCT05701709
- Phase: PHASE1
- Status: RECRUITING
- Sponsor: Shanghai Hengrui Pharmaceutical Co., Ltd.
- Conditions: Advanced Solid Tumors
- Interventions: SHR-A2102
- Enrollment: 395
- Primary outcome: Number of participants with adverse events
- Primary outcome: Maximum tolerated dose (MTD)
- Primary outcome: Recommended Phase 2 dose (RP2D)
- Primary outcome: Dose Limiting Toxicity (DLT)

## Indexed commentary on SHR-A2102 so far

Podcasts, YouTube videos and X posts we have indexed that name the trial. This is where a report starts, not where it ends: the build searches for more, so finished reports usually cover more than this.

- X threads: 4
- Bluesky threads: 2

## Order

Focused, $750, price fixed at order: https://www.erudio.com/contact?report=shr-a2102-nct05701709